Table 1 Demographic data of healthy controls (HC), end-stage renal disease patients (ESRD), and renal transplant recipients (Tx)
|  | HC (n = 31) | ESRD (n = 18) | Tx (n = 90) |
|---|---|---|---|
Age (years, median, IQR) | 43 (35–54) | 65 (51–73) | 56 (45–63) |
Sex (n, %) | |||
 Female | 17 (55) | 6 (33) | 27 (30) |
 Male | 14 (45) | 12 (67) | 63 (70) |
Days post-transplant (median, IQR) | – | – | 410 (22–3452) |
Type of donor (n, %) | |||
 Living | – | – | 17 (19) |
 Deceased | – | – | 73 (81) |
Graft No. (n, %) | |||
 First | – | – | 82 (91) |
 Second | – | – | 7 (8) |
 Third | – | – | 1 (1) |
Delayed graft function (n, %) | – | – | 9 (10) |
Cold ischemia time (min, median, IQR) | – | – | 765 (485–984) |
GFR ml/min (median, IQR) | – | – | 40 (24–55) |
Serum creatinine (median, IQR) | – | – | 1.8 (1.3–2.8) |
Previous CMV infection | – | – | 23 (26) |
Previous BKVN (n, %) | – | – | 3 (3) |
Patients with previous rejection (n, %) | |||
 Yes | – | – | 26 (29) |
 No | – | – | 64 (71) |
Protein/creatinine ratio g/mol (median, IQR) | – | – | 24 (13–48) |
CRP mg/l (median, IQR) | – | – | 10 (2–26) |
Etiology of the end stage renal disease (n, %) | Â | Â | Â |
Chronic glomerulonephritis | – | 6 (33) | 32 (36) |
Diabetes | – | 4 (22) | 11 (12) |
Hypertension/ischemic | – | – | 4 (4) |
ADPKD | – | 2 (11) | 10 (11) |
Hereditary/ congenital | – | 1 (6) | 8 (9) |
Others | – | 3 (17) | 15 (17) |
Unknown | – | 2 (11) | 10 (11) |
Induction immunosuppression (number and percentage) | |||
 Basiliximab |  |  | 77 (85.6) |
 ATG |  |  | 13 (14.4) |
Maintenance immunosuppression (number and percentage of patients) | |||
 Ciclosporine | – | – | 41 (46) |
 Tacrolimus | – | – | 44 (49) |
 MMF | – | – | 75 (83) |
 Steroids | – | – | 86 (96) |
 Everolimus | – | – | 3 (3) |
 Azathioprine | – | – | 1 (1) |